Korro Bio Strengthens Leadership Team With Appointment of Howard Stern M.D., Ph.D. as Chief Scientific Officer

- Adds deep expertise in novel therapeutic modalities and translational science -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Howard Stern, M.D., Ph.D. as Chief Scientific Officer. Dr. Stern is a seasoned biotechnology executive with extensive experience in drug discovery and development, ranging from preclinical research to translational studies in clinical trials. Dr. Stern joins Korro from FogPharma, where he served as the Chief Scientific Officer.

“I am delighted to welcome Howard to our team. Throughout his career, he has applied his expertise in human genetics and translational studies to advance novel platforms and drug modalities,” said Ram Aiyar, Ph.D., Chief Executive Officer of Korro. “Howard’s experience complements the existing leadership team as we leverage our RNA editing platform to rapidly advance a broad pipeline of programs to the clinic.”

Prior to his role at FogPharma, Dr. Stern was Vice President of Translational Sciences at Juno Therapeutics, where he oversaw the pharmacology and correlative biomarker studies for engineered cellular therapies. In the early part of his career, Dr. Stern held scientific roles of increasing responsibility at Genentech and Infinity Pharmaceuticals. He holds an M.D. and Ph.D. in biochemistry from the University of Washington and completed his residency at Brigham and Women’s Hospital.

“Korro’s oligonucleotide platform for RNA editing is an elegant approach to generate novel medicines that overcome many challenges facing current gene therapy and gene editing methodologies,” said Dr. Stern. “The transient nature of Korro’s RNA editing technology enables a unique, titratable dosing regimen for genetic medicines. This paradigm opens up the potential to expand beyond rare diseases into treating large patient populations. I’m thrilled to join Korro as we advance the next generation of RNA therapeutics for patients with unmet medical needs.”

About Korro Bio, Inc.

Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. The synthetic oligonucleotide platform, OPERA^TM, is a modular drug discovery engine that combines proprietary data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety. As a result, Korro’s portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is located in Cambridge, Mass. For more information, visit korrobio.com.

Media Contact
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936